Oslo, 18 January 2024: Reference is made to the stock exchange announcement
published by Observe Medical ASA (the "Company" or "Observe Medical") on 12
December 2023 regarding the final results of the rights issue of minimum
69,230,770 new shares and maximum 211,538,461 new shares in the Company at a
subscription price of NOK 0.26 per share (the "Rights Issue").

The Company aimed to raise between minimum NOK 18 million and maximum NOK 55
million in gross proceeds in the Rights Issue.

The total gross proceeds from the Rights Issue were NOK 35,670,322.48, of which
NOK 21,525,405.98 was settled by way of cash payment and NOK 14,144,916.50 was
settled by way of set-off against the shareholder loans (as further described in
the minutes from the extraordinary general meeting held by the Company on 22
November 2023). The Rights Issue raised net cash proceeds of approximately NOK
16 million.

The Rights Issue was accordingly subscribed by approximately 65% of the maximum
gross proceeds.

The use of the proceeds from the Rights Issue was described as follows in the
prospectus for the Rights Issue:

 i. The minimum proceeds from the Rights Issue will cover the working capital
needs in relation to the ramp up of production and sale of the Unometer
Portfolio.

Any excess proceeds in the Rights Issue will be used for